Serological biomarkers predict immune-related adverse events and clinical benefit in patients with advanced gastrointestinal cancers

BACKGROUND: Immune checkpoint inhibitors (ICIs) have dramatically improved survival in advanced gastrointestinal (GI) cancer patients, but also resulted in immune-related adverse events (irAEs). This study aimed to evaluate serological biomarkers of irAEs and treatment response in GI cancer patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yanni, Zou, Jianling, Li, Yun, Jiao, Xi, Wang, Yujiao, Zhuo, Na, Gao, Mengting, Gong, Jifang, Li, Jian, Zhang, Xiaotian, Wang, Xicheng, Peng, Zhi, Qi, Changsong, Wang, Zhenghang, Li, Jie, Li, Yan, Shen, Lin, Zhang, Henghui, Lu, Zhihao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9492966/
https://www.ncbi.nlm.nih.gov/pubmed/36159840
http://dx.doi.org/10.3389/fimmu.2022.987568

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9492966/
https://www.ncbi.nlm.nih.gov/pubmed/36159840
http://dx.doi.org/10.3389/fimmu.2022.987568

Ejemplares similares